Compare ACADIA Pharmaceuticals Inc. (ACAD) vs US Bancorp (USB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs US Bancorp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while US Bancorp trades at $61.13 (market cap $97.97B). The key difference: US Bancorp is far larger — about 21.8× ACADIA Pharmaceuticals Inc.'s market cap, and US Bancorp pays a 3.31% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | USB | |
|---|---|---|
Market Cap | $4.49B | $97.97B |
Sector | Health | Financials |
52-Week High | $28.06 | $62.89 |
52-Week Low | $20.06 | $43.94 |
Enterprise Value | $3.69B | — |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
U.S. Bancorp (USB) trades at $62.89, up 1.88% on the day, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company reported 2025 net income of $7.57 billion, with a net margin of 27.04%, and maintains a solid dividend history, including a recent $0.52 per share payout. Analyst consensus is mixed but leans positive, with a price target of $66.64.
USB's outlook is supported by robust profitability and strategic partnerships, but risks include interest rate sensitivity and competitive pressures. The stock offers value with a P/E of 13.17, though investors should monitor net cash flow trends and economic conditions affecting banking sector performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
